#PLSE

Lead report

Pulse Biosciences targets early October enrollment completion for 164-patient NANOPULSE-AF study (NASDAQ:PLSE)

Pulse Biosciences (PLSE) Q2 2026 earnings call: fast NANOPULSE-AF enrollment to early Oct, CE Mark timeline, revenue & cash runway.